

Part II Organizational Action *(continued)*

17 List the applicable Internal Revenue Code section(s) and subsection(s) upon which the tax treatment is based ▶ See attachment.

18 Can any resulting loss be recognized? ▶ See attachment.

19 Provide any other information necessary to implement the adjustment, such as the reportable tax year ▶ See attachment.

Under penalties of perjury, I declare that I have examined this return, including accompanying schedules and statements, and to the best of my knowledge and belief, it is true, correct, and complete. Declaration of preparer (other than officer) is based on all information of which preparer has any knowledge.

Sign Here
Signature ▶  Date ▶ December 1, 2023

Paid Preparer Use Only	Print your name ▶ <u>Edward Carr</u>	Preparer's signature	Title ▶ <u>Chief Accounting Officer</u>	Date	Check <input type="checkbox"/> if self-employed	PTIN
	Print/Type preparer's name				Firm's EIN ▶	
	Firm's name ▶				Phone no.	
	Firm's address ▶					

Dianthus Therapeutics OpCo, Inc. (F/K/A Dianthus Therapeutics, Inc.)

EIN: 84-2257157

Attachment to Form 8937

Form 8937, Part I, Box 10:

CUSIP number: 252828108 (formerly 55910K108)

Form 8937, Part II, Box 14:

On September 11, 2023, a wholly-owned direct corporate subsidiary of Magenta Therapeutics, Inc. ("Magenta") merged with and into Dianthus Therapeutics OpCo, Inc. (F/K/A Dianthus Therapeutics, Inc.) ("Dianthus OpCo"), with Dianthus OpCo surviving the merger. As a result, Dianthus OpCo became a wholly-owned subsidiary of Magenta. At the effective time of the merger, Magenta issued an aggregate of approximately 11,021,300 shares of Magenta common stock to Dianthus OpCo stockholders, based on an exchange ratio of approximately 0.2181 shares of Magenta common stock for each share of Dianthus OpCo common stock, excluding shares to be canceled pursuant to the merger agreement and dissenting shares.

Form 8937, Part II, Box 15:

Assuming the transaction qualifies as a reorganization within the meaning of Section 368(a) of the Internal Revenue Code of 1986, as amended (the "Code"), a Dianthus OpCo shareholder's aggregate tax basis in the Magenta common stock received will be the same as the aggregate tax basis of the Dianthus OpCo common stock surrendered in exchange therefor.

Form 8937, Part II, Box 16:

Assuming the transaction qualifies as a reorganization within the meaning of Section 368(a) of the Code, a Dianthus OpCo shareholder's aggregate tax basis in the Magenta common stock received will be the same as the aggregate tax basis of the Dianthus OpCo stock surrendered in exchange therefor. If a shareholder acquired Dianthus OpCo stock at different times or at different prices, the shareholder's tax basis in the shares of Magenta common stock received in the merger may be determined based on each block of Dianthus OpCo stock surrendered. Such shareholders should consult their own tax advisors regarding the identification of the basis of Magenta common stock received in the merger.

Form 8937, Part II, Box 17:

Sections 354, 358, and 368(a).

Form 8937, Part II, Box 18:

Assuming the transaction qualifies as a reorganization within the meaning of Section 368(a) of the Code, no loss will be recognized for tax purposes as a result of the merger.

Form 8937, Part II, Box 19:

The transaction occurred during the calendar year ending December 31, 2023.